Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer

Ławicki, Sławomir; Głażewska, Edyta Katarzyna; Sobolewska, Monika; Będkowska, Grażyna Ewa; Szmitkowski, Maciej

doi:10.3343/alm.2016.36.3.223

Cited by 29 publications

(30 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This conclusion is also in accordance with our previous papers in which the diagnostic criteria of selected cytokines and aforementioned tumor markers were evaluated in various gynecological malignancies [47, 48]. Diagnostic specificity (SP) reached very high and equal values for all biomarkers studied and this was in accordance [40, 43] with the available literature in the course of various malignant and benign diseases.…”

Section: Discussionsupporting

confidence: 91%

Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers

et al. 2017

Self Cite

View full text Add to dashboard Cite

BackgroundMMP-7 and TIMP-1 may play a role in the pathogenesis of cancer disease. In this study we investigated plasma levels of selected metalloproteinase and its tissue inhibitor in comparison to plasma levels of the commonly accepted tumor markers (CA 125 and HE4) in selected histological types of epithelial ovarian cancer patients as compared to control groups: patients with a benign ovarian tumor and healthy subjects. Plasma levels of MMP-7 and TIMP-1 were determined using ELISA, CA 125 and HE4 – by CMIA methods.ResultsPlasma levels of all biomarkers studied were significantly higher in ovarian cancer patients as compared to both control groups. MMP-7 demonstrated comparable to HE4 or CA125 values of diagnostic sensitivity (SE: 61%; 68%; 58%, respectively), specificity (SP: 95%; 95%; 98%, respectively), positive (PPV: 93%; 96%; 98%, respectively) and negative predictive values (NPV: 61%; 66%; 60%, respectively) in the groups tested. The combined use of the aforementioned biomarkers resulted in a further increase in diagnostic criteria and AUC, especially in the early stages of the disease.ConclusionsThese findings suggest the usefulness of combining MMP-7 with CA 125 and HE4 in the diagnosis of epithelial ovarian cancer as a new tumor marker panel.Electronic supplementary materialThe online version of this article (doi:10.1186/s13048-017-0338-z) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 91%

Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Increased expression of M-CSF and its receptor is correlated with poor prognosis in breast, ovarian and prostate cancer [5][6][7][8][9][10][11]. M-CSF has mainly been studied in breast carcinomas, where it is commonly expressed [12,13]. Several other candidate markers have also been implicated, paricularly those involved in tumor invasion.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis

Lubowicka

Zbucka-Krętowska

Sidorkiewicz

et al. 2019

Pathol. Oncol. Res.

Self Cite

View full text Add to dashboard Cite

Macrophage colony-stimulating factor (M-CSF), matrix metalloproteinase-2 (MMP-2) and its specific tissue inhibitor (TIMP-2) may play an important role in the pathogenesis of cancer disease. We investigated the plasma levels and diagnostic power (ROC curve analysis) of M-CSF, MMP-2, TIMP-2 and tumor markers CA 125 and SCC-Ag in cervical cancer (CC) patients as compared to control group. The study included 89 patients with cervical cancer. The control group consisted of 50 healthy, untreated women. The plasma levels of M-CSF, MMP-2 and TIMP-2 were determined using ELISA, CA 125 and SCC-Agby CMIA method. The median levels of M-CSF, TIMP-2, SCC-Ag and CA 125 in the entire group of CC were significantly different than compared to the healthy women group. MMP-2 showed the highest value of sensitivity from all examined parameters (in stage I of CC -93.10%, II -82.76%, III and IV -96.88%, total group -92.05%). The highest specificity was obtained by M-CSF (86%). The area under the ROC curve (AUC) of M-CSF (0.8051) was the largest of all the tested parameters (even higher than commonly used tumor markers) in the group of cervical cancer. The combination of M-CSF, MMP-2 or TIMP-2 with SCC antigen resulted in an increase AUCs in all cases (0.8760;0.7880;0.8081;respectively). The findings of this study suggest the usefulness of all examined parameters in the diagnostics of CC patients. Out of the tested substances, M-CSF also appears to be the best candidate for cancer diagnostics in all stages of the disease, based on ROC analysis.

show abstract

“…M‐CSF, a secreted cytokine, regulates the growth and differentiation of hematopoietic progenitor cells and functionally activates mature macrophages or neutrophils . It functions in the production of monocytes; but in pathological cases, induces cancer cell growth …”

Section: Introductionmentioning

confidence: 99%

Is there any potential anticancer effect of raloxifene and fluoxetine on DMBA‐induced rat breast cancer?

Tatar

İlhan

Susam

et al. 2019

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Breast cancer is the most common cancer among women in the world and the incidence is increasing alarmingly. It was aimed to determine the effect of raloxifene (RAL) and fluoxetine (FLX) on selected parameters in 7,12‐dimethylbenz(a)anthracene (DMBA)‐induced mammary carcinoma. Thirty‐two female Wistar albino rats were assorted into four groups: DMBA (group I), DMBA+RAL (group II), DMBA+FLX (group III), and DMBA+RAL+FLX (group IV). Mammary tissue vascular endothelial growth factor (VEGF), macrophage colony‐stimulating factor (M‐CSF), matrix metalloproteinase‐9 (MMP‐9), and tissue inhibitors of matrix metalloproteinase‐1 (TIMP‐1) levels were determined by the enzyme‐linked immunosorbent assay method. The tissue VEGF levels were lower in group IV compared with DMBA group. Decreased M‐CSF levels were observed in all therapeutic groups rather than the DMBA group, but the most effective decrease was found in group IV. Compared with the DMBA group, MMP‐9 levels were statistically significantly decreased in group II and group IV. However, TIMP‐1 levels were higher in the whole therapeutic groups rather than the DMBA group and the most effective increase was observed in group IV. Results of the present study suggest that combined therapy of RAL with FLX might lead to a better outcome targeting breast tumor.

show abstract

Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer

Cited by 29 publications

References 23 publications

Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers

Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers

Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis

Is there any potential anticancer effect of raloxifene and fluoxetine on DMBA‐induced rat breast cancer?

Contact Info

Product

Resources

About